INTRODUCTION
Effective oral drug delivery may depend upon several factors such as gastric emptying process, gastrointestinal transit time of dosage form, drug release from the dosage form and site of absorption of drugs. Most of the oral dosage forms possess physiological limitations such as variable gastrointestinal transit, because of variable gastric emptying, leading to non-uniform absorption proÞ les, incomplete drug release and shorter residence time of the dosage form in the stomach. This leads to incomplete absorption of drugs having absorption window, especially in the upper
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Design, Evaluation and Study of Effect of Hydrophilic Polymers on Release Rate of Antiulcer Floating Tablets
The hydrodynamic balanced system (HBS), also called Floating drug delivery system (FDDS), is an oral dosage form (capsule or tablet) designed to prolong the residence time of the dosage form within the GIT. It is a formulation of a drug with gel forming hydrocolloids meant to remain buoyant in the stomach contents. Drug dissolution and release from the dosage form retained in the stomach ß uids occur at the pH of the stomach under fairly controlled conditions. [2] The retentive characteristics of the dosage form are not signiÞ cant for the drugs that: 1. Are insoluble in intestinal ß uids 2. act locally exhibit site-speciÞ c absorption.
MATERIALS AND METHODS
Famotidine and Xanthan gum was gifted from Micro lab Hosur, HPMC K4 and HPMC K100 was gifted by Colorcon Asia Pvt. Ltd., Goa. Avicel PH-102 was obtained as gift sample from signet Chem Ltd, Mumbai and other reagents were obtained from the laboratory.
Preparation of gastro retentive ß oating tablets
Different tablet formulations were prepared by direct compression technique. All the powders were passed though 60 mesh sieve. The required quantity of drug, and low-density polymer were mixed thoroughly. Talc and magnesium stearate were Þ nally added as glidant and lubricant respectively. The blend was directly compressed (9mm diameter punches) using tablet compression machine. Each tablet contained 40mg of famotidine and others pharmaceutical ingredients used as shown in Table 1 .
Evaluation of powder blend [5] [6] [7] [8] Angle of repose: The angle of repose of powder blend was determined by the funnel method. The accurately weighed powder blend was taken in the funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touched the apex of the powder blend. The powder blend was allowed to ß ow through the funnel freely on to the surface. The diameter of the powder cone was measured and angle of repose was calculated using the following equation.
tan θ = h/r Where, h and r are the height and radius of the powder cone.
Bulk Density: Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. A quantity of 2 gm of powder blend from each formula, previously shaken to break any agglomerates formed, was introduced in to a 10 ml measuring cylinder. The initial volume was noted and the cylinder was allowed to fall under its own weight on to a hard surface from the height of 2.5 cm at second intervals. Tapping was continued until no further change in volume was noted. LBD and TDB were calculated using the following equations. Evaluation of Tablets Drug content [9] Five tablets were weighed individually and powdered. The powder equivalent to average weight of tablets was weighed and drug was extracted in 0.1 N HCl; the drug content was determined measuring the absorbance at 266.2 nm after suitable dilution using a Shimadzu UV-1601 UV/Vis double beam spectrophotometer.
Friability test
The friability of tablets was determined using Roche Friabilator. It is expressed in percentage (%). Ten tablets were initially weighed (W initial ) and transferred into friabilator. The friabilator was operated at 25rpm for 4 minutes or run up to 100 revolutions. The tablets were weighed again (W Þ nal ). The % friability was then calculated by -
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%F = 100 (1-W 0 /W) % Friability of tablets less than 1% are considered acceptable.
In vitro buoyancy studies [10] The in vitro buoyancy was determined by ß oating lag time method described by Dave B.S. [10] The tablets were placed in a 250 ml beaker containing 0.1 N HCl. The time required for the tablets to rise to the surface and ß oat was determined as ß oating lag time. The time between introduction of dosage form and its buoyancy in 0.1 N HCl and the time during which the dosage form remain buoyant were measured. The time taken for dosage form to emerge on surface of medium called Floating Lag Time (FLT) and total duration of time by which dosage form remain buoyant is called Total Floating Time (TFT).
In Vitro dissolution studies [4] The release rate of famotidine from ß oating tablets was determined using the United States Pharmacopoeia (USP) XXIV dissolution testing apparatus II (paddle method). The dissolution test was performed using 900 ml of 0.1 N HCl, at 37 ± 0.5°C and 75 rpm. A sample (5 ml) of the solution was withdrawn from the dissolution apparatus hourly for eight hours, and the samples were replaced with fresh dissolution medium. The samples were diluted to a suitable concentration with 0.1N HCl. Absorbance of these solutions was measured at 266.2 nm using a Shimadzu UV-1601 UV/Vis double beam spectrophotometer. Cumulative percentage of drug release was calculated using the equation obtained from a standard curve.
Swelling index [11] The swelling index of tablets was determined n 0.1 N HCl (pH 1.2) at room temperature. The swollen weight of the tablets was determined at predeÞ ned time intervals. The . The tablets were evaluated for buoyancy lag time. The method followed is same as that of buoyancy test.
Stability study [12] [13] [14] Gastro retentive tablets of famotidine formulated in the present study were subjected to accelerated stability studies. Stability studies of the prepared formulations were performed at ambient humidity conditions, at room temperature, at 40 o c and 4 o c for a period up to 30 days. The samples were withdrawn after periods of 15 days and 30 days; analyzed for its appearance, hardness, friability, ß oating time, drug content and in vitro release.
RESULTS AND DISCUSSION
Evaluation of tablet formulations
Pre-compression parameters a. Angle of Repose (θ): The angle of repose for the formulated blend was carried out. It concludes all the formulations blend were found to be in the range 24 0 .88' to 29.30'. Talc  2  2  2  2  2  2  2  2  2  2 #All quantities were in milligrams. #All the batches contained 1% w/w talc and 0.5% w/w magnesium stearate Design, evaluation & study of effect of hydrophilic polymers on release rate of antiulcer ß oating tablets b. Compressibility Index: Compressibility index was carried out and found to be 12.34% to 16.30% indicating the powder blend has the required ß ow property for compression.
Post-compression parameters a. Friability Test: The % friability was less than 1% in all the formulations ensuring that the tablets were mechanically stable. b. Drug Content Uniformity: The percentage of drug content for FT1 to FT10 was found to be in between 97.11% to 99.69% of famotidine, it complies with ofÞ cial speciÞ cations as shown in Table 2 .
In vitro buoyancy study
On immersion in 0.1N HCl solution pH (1.2) at 37 0 C, the tablets floated, and remained buoyant without disintegration. From the results it can be concluded that the batch containing only HPMC polymer showed good total ß oating time (TFT). Formulation containing HPMC K4M, HPMC K100M and Xanthan gum showed good FLT of 45 sec, while the formulation containing Xanthan gum (alone) did not ß oat more than 1.5 hrs. This may be due to the nature of polymer and gas generating agent, which were kept constant in the present study. The gas generated cannot be entrapped inside the gelatinous layer, and it escapes leading to variation in FLT and TFT.
Swelling study
Swelling study was performed on all the batches (FT1 to FT10) for Þ ve hours. The results of swelling index were shown in Table 3 and in Figure 1 .
In the present study, the higher swelling index was found for tablets of batch FT10 containing HPMC K4M, HPMC K100M and Xanthan gum having nominal viscosity of more than 1, 04,000 cps. Thus, the viscosity of the polymer had major inß uence on swelling process, matrix integrity, as well as ß oating capability, hence from the above results it can be concluded that linear relationship exists between swelling process and viscosity of polymer.
Effect of hardness on buoyancy lag time
The effect of hardness on buoyancy lag time for batch FT10 was studied. Table 4 and. Buoyancy lag time (sec) vs. hardness (kg/ cm 2 ) plotted and shown in Figure 2 .
In vitro dissolution study and kinetic modeling of drug release
From the in vitro dissolution data it was found that Time  FT1  FT2  FT3  FT4  FT5  FT6  FT7  FT8  FT9  FT10   1 hr  32  33  31  40  35  29  36  48  30  42  2 hrs  39  38  38  51  42  36  46  59  41  51   3 hrs  41  43  44  62  49  48  56  65  46  67   4 hrs  49  49  52  73  57  59  64  78  54  76   5 hrs  56  65  68  90  68  62  77  82  60  91 formulation FT1 to FT9 released more than 90% of drug before eight hours of the study indicating that the polymer amount is not sufÞ cient to control the drug release. While FT8 and FT10 containing Xanthan gum and HPMC K100M released more than 90% of drug with in eight hours. It concludes that F10 had better controlled release than the other formulation.
The release data obtained for formulations FT1 to FT10 were tabulated in Table 5 , Figure 3 shows the plot of cumulative per cent drug released as a function of time for different formulations. The results obtaining in vitro release studies were plotted in different models of data treatment as follows: zero order rate kinetics, Þ rst order rate kinetics, Higuchi's classical diffusion equation, Peppas exponential equation, Hixson-Crowell erosion equation.
The kinetic values obtained for formulation FT10 were shown in Table 6 . Design, evaluation & study of effect of hydrophilic polymers on release rate of antiulcer ß oating tablets 
Stability study
The stability study results obtained were shown in Table 7 and 8. The results revealed that no signiÞ cant changes in appearance, ß oating time, drug content, hardness, friability, and in vitro release for FT10 formulation when it was stored at the three different storage conditions.
CONCLUSION
The aim of the study was to study the effect of various hydrophilic polymers on in vitro release rate from gastro retentive ß oating tablet of famotidine based on a low density polymer.
Different types of matrix forming polymers -HPMC K4 M, HPMC K100 M, Xanthan gum were studied. The tablets eroded upon contact with the release medium, and the relative importance of drug diffusion, polymer swelling and tablet erosion for the resulting release patterns varied signiÞ cantly with the type of matrix former. The release rate could effectively be modiÞ ed by varying the ''matrixforming polymer/low density polymer'' ratio, the tablet geometry (radius), the type of matrix-forming polymer, the use of polymer blends and the addition of water-insoluble Þ llers (such as Avicel PH-102). The ß oating behavior of the low density drug delivery systems could successfully be combined with accurate control of the drug release patterns. The batch optimization was done using HPMC K4M, HPMC K100 M and Xanthan gum as matrixing polymers as they gave optimum FLT as well as long acting effect and no/ least eroding effect. It was also found that the tablet formulations released more than 90% drug in 8 hours as desired.
The use of HPMC K4 M, HPMC K100 M polymer in matrix tablets as density reducing agents has given a different look, Xanthan gum was used as release retardant polymer. During the study with the polymer various characteristics of the material observed include: highly porous spherical structure, good compressibility, good ß ow property with drug and other polymers, no signiÞ cant effect on drug release and compatibility with drug and other polymers as seen through IR spectra.
Thus the above studies reveals that HPMC K4M, HPMC K100 M and Xanthan gum can be successfully used in the formulation of famotidine sustained release gastro retentive ß oating drug delivery system using low density polymer.
